Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of July 2016
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
AstraZeneca PLC H1 2016 Results
Tomorrow, Thursday 28 July 2016, AstraZeneca PLC will publish its H1 2016 results at 07:00 UK time.
An analyst presentation will take place at 12:00 UK time and will be accessible by a choice of two routes:
Audio webcast
If you wish to participate in the Q&A session, please dial in five minutes prior to the start time using the numbers and conference code below:
|
|
Freephone |
Local |
|
United Kingdom |
0800 279 4992 |
+44 (0) 20 3140 8286 |
|
United States |
1877 280 1254 |
+1 718 354 1157 |
|
Sweden |
0200 883 440 |
+46 (0) 8 5352 6408 |
Conference code: 4185930
Listen-only audio webcast
If you wish to listen to the audio webcast, please dial in five minutes prior to the start time using the numbers and conference code below:
|
|
Freephone |
Local |
|
United Kingdom |
0800 279 4977 |
+44 (0) 20 3427 1917 |
|
United States |
|
+1 718 354 1158 |
|
Sweden |
|
+46 (0) 8 5051 3793 |
Conference code: 4185930
A replay and a transcript from the audio webcast will be made available shortly after the conclusion of the event on http://www.astrazeneca.com/investors.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AstraZeneca PLC
Date: 27 July 2016
By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary